Thanks Thanks:  0
Recommend Recommend:  0
Likes Likes:  0
  1. #1
    MuscleChemistry Guru Board Certified CPH
    Dean Destructo's Avatar
    Join Date
    May 2016
    Posts
    1,279
    Rep Power
    2147484934

    Default Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels:

    Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.
    Basaria S1, Harman SM2, Travison TG3, Hodis H4, Tsitouras P5, Budoff M6, Pencina KM1, Vita J7, Dzekov C8, Mazer NA9, Coviello AD10, Knapp PE10, Hally K1, Pinjic E1, Yan M4, Storer TW1, Bhasin S1.
    Author information
    Abstract
    IMPORTANCE:
    Testosterone use in older men is increasing, but its long-term effects on progression of atherosclerosis are unknown.

    OBJECTIVE:
    To determine the effect of testosterone administration on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels.

    DESIGN, SETTING, AND PARTICIPANTS:
    Testosterone's Effects on Atherosclerosis Progression in Aging Men (TEAAM) was a placebo-controlled, double-blind, parallel-group randomized trial involving 308 men 60 years or older with low or low-normal testosterone levels (100-400 ng/dL; free testosterone <50 pg/mL), recruited at 3 US centers. Recruitment took place between September 2004 and February 2009; the last participant completed the study in May 2012.

    INTERVENTIONS:
    One hundred fifty-six participants were randomized to receive 7.5 g of 1% testosterone and 152 were randomized to receive placebo gel packets daily for 3 years. The dose was adjusted to achieve testosterone levels between 500 and 900 ng/dL.

    MAIN OUTCOMES AND MEASURES:
    Coprimary outcomes included common carotid artery intima-media thickness and coronary artery calcium; secondary outcomes included sexual function and health-related quality of life.

    RESULTS:
    Baseline characteristics were similar between groups: patients were a mean age of 67.6 years; 42% had hypertension; 15%, diabetes; 15%, cardiovascular disease; and 27%, obesity. The rate of change in intima-media thickness was 0.010 mm/year in the placebo group and 0.012 mm/year in the testosterone group (mean difference adjusted for age and trial site, 0.0002 mm/year; 95% CI, -0.003 to 0.003, P = .89). The rate of change in the coronary artery calcium score was 41.4 Agatston units/year in the placebo group and 31.4 Agatston units/year in the testosterone group (adjusted mean difference, -10.8 Agatston units/year; 95% CI, -45.7 to 24.2; P = .54). Changes in intima-media thickness or calcium scores were not associated with change in testosterone levels among individuals assigned to receive testosterone. Sexual desire, erectile function, overall sexual function scores, partner intimacy, and health-related quality of life did not differ significantly between groups. Hematocrit and prostate-specific antigen levels increased more in testosterone group.

    CONCLUSIONS AND RELEVANCE:
    Among older men with low or low-normal testosterone levels, testosterone administration for 3 years vs placebo did not result in a significant difference in the rates of change in either common carotid artery intima-media thickness or coronary artery calcium nor did it improve overall sexual function or health-related quality of life. Because this trial was only powered to evaluate atherosclerosis progression, these findings should not be interpreted as establishing cardiovascular safety of testosterone use in older men.

    TRIAL REGISTRATION:
    clinicaltrials.gov Identifier: NCT00287586.
     

  2. #2
    MuscleChemistry Registered Member Board Certified MD
    NAIR's Avatar
    Join Date
    Jun 2006
    Location
    Somewhere over the rainbow
    Posts
    4,742
    Rep Power
    3768116

    Default

    Interesting, I suppose, but there's not much insight to gain from this study for those who are exceeding TRT dosing.
     

  3. #3
    Presser's Avatar
    Join Date
    May 2002
    Posts
    41,686
    Rep Power
    2147525355

    Default

    Quote Originally Posted by NAIR View Post
    Interesting, I suppose, but there's not much insight to gain from this study for those who are exceeding TRT dosing.
    Who does that? Exceed prescribed dosage , no way no how lol
    Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels:

  4. #4
    MuscleChemistry Guru Board Certified DMD
    bigdaddyo1617's Avatar
    Join Date
    Apr 2014
    Location
    springfield,ma
    Posts
    835
    Rep Power
    2147484492

    Default

    ������
    ONE MORE REP YEAH BUDDY

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  

Log in

Log in